Swedish Orphan Biovitrum (SOBI) investor relations material

Strategic direction and growth ambitions

• Aims to double revenue to SEK 55bn by 2030, driven by six major launches and five potential blockbusters.

• Focuses on rare diseases, expanding into broader populations with unmet needs.

• Global footprint expanded, with >100 launches in five years and new organizations in Japan, Australia, Korea, and Brazil.

• International sales share expected to exceed 20% by 2030, up from 7% in 2017.

• Maintains a patient-centric, science-driven approach while diversifying portfolio.

Financial performance and outlook

• 2025 revenue reached SEK 28.2bn, up 15% at constant exchange rates (CER), with a 40% adjusted EBITA margin.

• Delivered a 12% revenue CAGR from 2020–2025, with strong and consistent cash generation.

• 2026 revenue anticipated to grow at a low double-digit percentage at CER, with adjusted EBITA margin in the mid-30s.

• Key investments in 2021–2023 are driving current and future growth.

• Financial framework targets R&D at 11–14% of sales and margin expansion through operating leverage.

Product and pipeline highlights

• Six major launches planned: Altuvoct, Gamifant, Aspaveli, NASP, Tryngolza, and pozdeutinurad.

• Five assets have blockbuster potential, including Altuvoct (Haemophilia A), Gamifant (HLH/MAS), Aspaveli (C3G/IC-MPGN), Tryngolza (SHTG), and pozdeutinurad (progressive gout).

• Altuvoct FY 2025 sales exceeded SEK 6.8bn, with launches in 23 countries and further expansion planned.

• Doptelet grew 47% at CER in Q4 2025, expanding globally with strong uptake in Japan.

• Aspaveli received EU approval for C3G and IC-MPGN, with German launch in Q1 2026.